Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

MAO-A inhibitor phenelzine shows promise for treating recurrent prostate cancer

Feb. 17, 2020

Origin story helps ovarian cancer prognosis

Feb. 17, 2020

Domain Therapeutics patents mGluR4 positive allosteric modulators

Feb. 17, 2020

New IDO-1 inhibitors identified at Bristol-Myers Squibb

Feb. 17, 2020

Hinova Pharmaceuticals discovers new BRD4 inhibitors

Feb. 17, 2020

Bayer presents data from phase II/III FORT-1 study of rogaratinib

Feb. 17, 2020

Phase I data presented for fosciclopirox in advanced solid tumors

Feb. 17, 2020

BioBlocks and Visionary Pharmaceuticals disclose SGK1 inhibitors

Feb. 14, 2020

Arcus Biosciences divulges adenosine A2A and/or A2B receptor antagonists

Feb. 14, 2020

IMP-4297 studied in phase III as maintenance treatment for advanced ovarian cancer

Feb. 14, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...